What is the main difference between GHRP-2, GHRP-6, and ipamorelin?

All three act on the same ghrelin / growth-hormone-secretagogue receptor, so the real difference is selectivity. GHRP-6 is most associated with strong appetite and hunger signalling; GHRP-2 is a middle ground with a more moderate appetite effect but more reported cortisol and prolactin activity; ipamorelin is the most selective, with the least reported appetite, cortisol, and prolactin activity of the three.

Which of the three causes the most hunger?

GHRP-6 is the one most associated in the research literature with a strong appetite effect, because it closely mimics ghrelin, the body's own hunger hormone. GHRP-2 is usually described as more moderate, and ipamorelin as the mildest of the three on appetite. All of this is reported research characterization, not a certain or predictable effect, and human data is limited.

What is the regulatory status of GHRP-2, GHRP-6, and ipamorelin?

None of them is approved. To be precise, each one is not FDA-approved. They are sold for laboratory research use only, not for human use, and have not been proven safe or effective in people. Their effects in humans are still being studied, and the research-grade supply chain adds contamination and mislabeling risk on top of that.

Performance

GHRP-2 vs GHRP-6 vs Ipamorelin: The Honest Three-Way Comparison

Q: Is ipamorelin actually safer than GHRP-2 or GHRP-6?

Ipamorelin is consistently described as more selective, with less reported cortisol and prolactin activity, which is why it has a gentler reputation. But that reputation is not settled by large controlled human trials, so it is a plausible profile rather than a proven safety claim. All three are research-grade peptides that are not FDA-approved, and each carries its own reported side effects.

By MrPepTalks Editorial · Updated 2026-07-08

GHRP-2, GHRP-6, and ipamorelin get lumped together constantly, and for a fair reason: all three are growth-hormone secretagogues that act on the same target, the ghrelin / growth-hormone-secretagogue receptor, and all three are commonly researched for prompting the pituitary to release its own growth hormone. But treating them as interchangeable misses the whole point of the comparison. The three pull apart on the axes people actually search for, appetite, cortisol, and prolactin, and they carry different depths of human evidence behind them. This guide maps those differences honestly. All three are research-grade peptides, not FDA-approved, and their effects in humans are still being studied.

What all three have in common

Start with the shared ground, because it explains why they get grouped. GHRP-2, GHRP-6, and ipamorelin are all synthetic growth-hormone-releasing peptides that act on the ghrelin receptor (GHS-R) rather than the separate GHRH receptor that peptides like sermorelin and CJC-1295 use. In the research literature they are commonly studied for triggering pulse-like releases of growth hormone, a different pathway and a different release pattern than a GHRH analog. That is why forums so often discuss pairing one of these ghrelin-receptor peptides with a GHRH-analog peptide rather than choosing between the two families. If you want the neutral background on that other family, our data sheet on sermorelin sits at /peptides/sermorelin, and the wider peptide-versus-hormone picture is covered at /learn/peptides-vs-hgh-injections.

The real difference: appetite, cortisol, and prolactin

Here is the distinction that actually separates the three, and the one marketing tends to blur. Because they all hit the same receptor, the meaningful contrast is not whether they raise growth-hormone markers, but how selective they are, that is, how much they also stir up appetite and the stress-and-lactation hormones cortisol and prolactin. GHRP-6 is the one most associated in the research literature with strong appetite and hunger signalling, an effect that comes directly from its ghrelin-mimicking action. GHRP-2 is often described as having a more moderate appetite effect than GHRP-6, but it has been reported to raise cortisol and prolactin somewhat more than ipamorelin does. Ipamorelin is the selective outlier: it is frequently characterized as one of the more selective peptides in its class, with the least reported appetite, cortisol, and prolactin activity of the three. Selectivity is the single headline reason people bring ipamorelin up.

GHRP-6: the strong-appetite one

GHRP-6 is one of the earliest peptides in this class, and its defining feature in the literature is a pronounced hunger response, a direct consequence of how closely it mimics ghrelin, the body's own hunger hormone. That appetite signalling is exactly why it is discussed both as a talking point and as a drawback, depending on the goal. Commonly reported side effects also include water retention, flushing, tingling, and local reactions at the study contact point, and its off-target cortisol and prolactin activity is generally described as higher than ipamorelin's. Its human evidence is thin: most of the record is preclinical and mechanistic, so its human picture is not well characterized. Our neutral data sheet is at /peptides/ghrp-6, and the honest verdict deep-dive sits at /verdicts/ghrp-6-research-verdict.

GHRP-2: the middle ground

GHRP-2 is often positioned as a middle option: a more moderate appetite effect than GHRP-6, but with more reported cortisol and prolactin activity than the selective ipamorelin. It has been studied in humans as a growth-hormone secretagogue, so there is some human pharmacology on record for how it moves growth-hormone markers, but controlled outcome trials in healthy people for the physique and recovery goals it is marketed for are limited. Commonly reported side effects overlap with the rest of the class: water retention, flushing, headache, and local reactions at the study contact point, plus the cortisol and prolactin bump that its lower selectivity implies. You can read the neutral data sheet at /peptides/ghrp-2 and the full honest verdict at /verdicts/ghrp-2-research-verdict.

Ipamorelin: the selective one

Ipamorelin is the peptide people reach for when selectivity is the priority. In the research literature it is frequently described as one of the first selective growth-hormone secretagogues, with less reported impact on cortisol and prolactin, and a milder appetite effect, than the two GHRPs. That cleaner reported profile is the entire reason it gets recommended over GHRP-6 and GHRP-2 in forum discussions. The honest caveat is that its human safety and outcome data is limited, so the gentler reputation, while consistent across the literature, is not settled by large controlled human trials. Its neutral data sheet is at /peptides/ipamorelin and the verdict deep-dive at /verdicts/ipamorelin. Ipamorelin is also the peptide most often compared one-to-one against GHRH-analog peptides, which we cover at /compare/ipamorelin-vs-sermorelin and /compare/cjc-1295-vs-ipamorelin.

How strong is the evidence, really?

Be honest about the evidence base, because it is the part the marketing skips. None of the three is backed by the kind of large, controlled human outcome trials that would let anyone claim a real-world result. GHRP-2 has the most human pharmacology of the group, mostly measuring how it shifts growth-hormone markers, while GHRP-6 and ipamorelin lean more heavily on preclinical and mechanistic work. Across all three, raising a growth-hormone or IGF-1 lab marker is not the same as delivering the leaner, stronger, or faster-recovering body the ads imply, and that translation step is exactly where the evidence thins out or goes missing. Every one of them is not FDA-approved and is sold for laboratory research use only, not for human use. If you want a primer on reading these studies critically, start at /learn/what-are-peptides.

The cons and the sourcing reality

The full picture includes the downsides, and they cut across all three. Commonly reported side effects for the group include water retention, flushing, tingling or lightheadedness, headache, and local reactions at the study contact point, with GHRP-6's stronger appetite effect and the two GHRPs' higher reported cortisol and prolactin activity as the notable differences from ipamorelin. Because large long-term human trials are missing for every one of them, the complete side-effect profile is simply not well characterized. On top of that sits a supply-safety problem specific to the research-grade market: gray-market vials can be underdosed, mislabeled, or contaminated with endotoxins or heavy metals, and none of that is visible in the vial. The thing that actually varies between vendors is quality control, whether third-party purity and identity testing is published, which is a sourcing question, not an efficacy claim. We keep a running summary of the group's downsides at /learn/common-peptide-side-effects, and cover legal status at /learn/is-my-peptide-legal-2026.

So which one is the answer?

Framed as a straight better-or-worse contest, the question misses what the three-way spread is really about. All three act on the same receptor and share the same honest evidence gap, so the meaningful axis is selectivity: GHRP-6 leans hardest into appetite, GHRP-2 sits in the middle with more reported cortisol and prolactin activity, and ipamorelin is the selective end of the spectrum. Which of those tradeoffs matters depends entirely on what a researcher is studying, and none of the three has the controlled human outcome data to earn a real-world recommendation. Whatever the goal, two things stay true for every one of them: they are not FDA-approved, and their effects in humans are still being studied.